Optimization and mechanistic studies of halogenated phenazines and quinolines as anti-tuberculosis therapeutics

卤代吩嗪和喹啉类抗结核药物的优化及机理研究

基本信息

  • 批准号:
    10377920
  • 负责人:
  • 金额:
    $ 19.01万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-03-25 至 2024-02-29
  • 项目状态:
    已结题

项目摘要

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is responsible for staggering levels of global morbidity and mortality, with ~1.7 million deaths and ~10 million new cases each year. The shortcomings of currently available TB drugs hamper resolution of the ongoing TB crisis. The current “short course” regimen involves a cocktail of four front-line drugs administered for 6-9 months. The emergence of drug-resistant Mtb strains has complicated the already difficult task of treating TB. Driven by patient noncompliance and poor drug efficacy, ~500,000 cases of Multidrug-Resistant TB (MDR-TB) occur each year that are resistant to the two first-line drugs rifampicin (RIF) and isoniazid (INH). There is also evidence of Extensively (XDR-TB) and Totally Drug Resistant Mtb (TDR-TB), which reduce the number of therapeutics to few and none, respectively [3]. There is an urgent need for potent drugs with novel modes of action able to kill drug-resistant Mtb [4]. The ability of Mtb to establish persistent, latent infections in which Mtb are sequestered within granulomas is a hallmark of TB disease. Recent studies suggest that conditions within this lesion (i.e., hypoxia, low pH) induce a dormant metabolic state that renders bacilli phenotypically drug tolerant. Very few compounds have been identified that are active against slow-growing, dormant “persisters”. New drugs that will effectively eradicate such phenotypically resistant “persisters” may be the key to shortening treatment regimens. Our discovery of novel natural-product inspired compounds known as halogenated phenazines (HPs) that exert potent, highly selective antimicrobial activity against Mycobacterium tuberculosis provides the premise for this project. In Aim 1, we will employ a pipeline of antimicrobial assays to evaluate a library of HP analogs as well as structurally related halogenated quinolines (HQs) to define structure-activity relationships and identify optimal lead compounds. We will also work to fully understand the unique mechanism of action of HPs and HQs which appear to kill bacteria by sequestration of cytoplasmic iron. In Aim 2, in vitro ADME and in vivo PK studies will inform medicinal chemistry optimization needs and progress top compounds towards in vivo efficacy studies. To achieve compounds with enhanced pharmacological properties and in vivo performance, we will also test prodrug analogs of the best lead compounds. Completion of the proposed specific aims will yield critical knowledge about the structure-activity relationships (SAR), ADME and PK properties and mechanism of action of the HP/HQ compounds that will serve as a foundation for future lead optimization and in vivo efficacy studies.
结核病(TB),由结核分枝杆菌(Mtb)引起,是造成惊人的 全球发病率和死亡率水平,分别约为170万例死亡和1000万例新发病例 年目前可用的结核病药物的缺点阻碍了正在进行的结核病的解决 危机目前的“短期”方案包括四种一线药物的混合物, 6-9个月。耐药结核分枝杆菌菌株的出现使本已困难的 治疗结核病的任务。由于患者不依从和药物疗效差,约50万例 耐多药结核病(MDR-TB)每年都会发生,对两种一线药物具有耐药性 利福平(RIF)和异烟肼(INH)。也有证据表明广泛耐药结核和完全耐药结核 耐药结核病(TDR-TB),这减少了治疗的数量很少,没有, 分别为[3]。迫切需要具有新的作用模式的强效药物, 耐药结核分枝杆菌[4]。Mtb建立持续性潜伏感染的能力,其中Mtb 是结核病的标志。最近的研究表明, 该病变内的状况(即,缺氧、低pH)诱导休眠代谢状态, 杆菌表型耐药。很少有化合物已被确定是积极的 对抗生长缓慢休眠的“坚持者”新的药物将有效地根除这种 表型耐药的“坚持者”可能是缩短治疗方案的关键。 我们发现了新的天然产物灵感化合物称为卤代 吩嗪类药物(HP)对分枝杆菌具有强效、高选择性的抗菌活性 结核病为该项目提供了前提。在目标1中,我们将采用 抗微生物测定以评估HP类似物以及结构上相关的卤代 喹啉(HQ),以确定结构-活性关系,并确定最佳的先导化合物。 我们还将努力充分了解HP和HQ的独特作用机制, 似乎通过螯合细胞质铁来杀死细菌。在目标2中,体外ADME和体内 PK研究将告知药物化学优化需求和进展顶级化合物 用于体内功效研究。为了获得具有增强的药理学活性的化合物, 为了测试先导化合物的前体药物性质和体内性能,我们还将测试最佳先导化合物的前体药物类似物。 完成提出的具体目标将产生关于结构-活性的关键知识 HP/HQ化合物的SAR、ADME和PK性质以及作用机制 这将作为未来铅优化和体内功效研究的基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert William Huigens其他文献

Robert William Huigens的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert William Huigens', 18)}}的其他基金

Optimization and mechanistic studies of halogenated phenazines and quinolines as anti-tuberculosis therapeutics
卤代吩嗪和喹啉类抗结核药物的优化及机理研究
  • 批准号:
    10193679
  • 财政年份:
    2021
  • 资助金额:
    $ 19.01万
  • 项目类别:
Indole Alkaloids and Phenazine Antibiotics: New Platforms for Drug Discovery
吲哚生物碱和吩嗪抗生素:药物发现的新平台
  • 批准号:
    9983101
  • 财政年份:
    2018
  • 资助金额:
    $ 19.01万
  • 项目类别:
Indole Alkaloids and Phenazine Antibiotics: New Platforms for Drug Discovery
吲哚生物碱和吩嗪抗生素:药物发现的新平台
  • 批准号:
    10451729
  • 财政年份:
    2018
  • 资助金额:
    $ 19.01万
  • 项目类别:
Indole Alkaloids and Phenazine Antibiotics: New Platforms for Drug Discovery
吲哚生物碱和吩嗪抗生素:药物发现的新平台
  • 批准号:
    10217189
  • 财政年份:
    2018
  • 资助金额:
    $ 19.01万
  • 项目类别:

相似海外基金

SBIR Phase II: Development of a urine dipstick test that can guide immediate and appropriate antibiotic therapy for treatment of complicated urinary tract infections
SBIR II 期:开发尿液试纸测试,可以指导复杂尿路感染的立即和适当的抗生素治疗
  • 批准号:
    2213034
  • 财政年份:
    2023
  • 资助金额:
    $ 19.01万
  • 项目类别:
    Cooperative Agreement
Personalized Antibiotic Therapy in the Emergency Department: PANTHER Trial
急诊科的个性化抗生素治疗:PANTHER 试验
  • 批准号:
    10645528
  • 财政年份:
    2023
  • 资助金额:
    $ 19.01万
  • 项目类别:
Strategies for improving the efficacy of combinatorial antibiotic therapy in chronic infections
提高慢性感染联合抗生素治疗疗效的策略
  • 批准号:
    10736285
  • 财政年份:
    2023
  • 资助金额:
    $ 19.01万
  • 项目类别:
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures
一种治疗感染性骨折的新型骨靶向抗生素疗法
  • 批准号:
    10603486
  • 财政年份:
    2023
  • 资助金额:
    $ 19.01万
  • 项目类别:
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
  • 批准号:
    449379
  • 财政年份:
    2020
  • 资助金额:
    $ 19.01万
  • 项目类别:
    Studentship Programs
Sex-Specific Differences in End-of-Life Burdensome Interventions and Antibiotic Therapy in Nursing Home Residents With Advanced Dementia
患有晚期痴呆症的疗养院居民的临终干预和抗生素治疗的性别差异
  • 批准号:
    422034
  • 财政年份:
    2020
  • 资助金额:
    $ 19.01万
  • 项目类别:
Optimizing outpatient parenteral antibiotic therapy to support hospital-in-the-home program across the unique environmental conditions of Australia
优化门诊肠外抗生素治疗,以支持澳大利亚独特环境条件下的家庭医院计划
  • 批准号:
    nhmrc : 1197866
  • 财政年份:
    2020
  • 资助金额:
    $ 19.01万
  • 项目类别:
    Investigator Grants
Resistance evolution in the presence of combination antibiotic therapy
联合抗生素治疗下耐药性的演变
  • 批准号:
    2241853
  • 财政年份:
    2019
  • 资助金额:
    $ 19.01万
  • 项目类别:
    Studentship
Host-pathogen interactions in antibiotic therapy for listeriosis
李斯特菌病抗生素治疗中宿主与病原体的相互作用
  • 批准号:
    18K07106
  • 财政年份:
    2018
  • 资助金额:
    $ 19.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Multipurpose targeted nano-antibiotic therapy to fight tough infection in bones
多用途靶向纳米抗生素疗法可对抗骨骼中的严重感染
  • 批准号:
    9788269
  • 财政年份:
    2018
  • 资助金额:
    $ 19.01万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了